2023 World Conference on Lung Cancer (Posters)-P1.24. Spatially Defined Immune Response Signatures in 5µm Tumor Section of Resected T1-2N0M0 Lung Cancer Predict Clinical Outcome

P1.24. Spatially Defined Immune Response Signatures in 5µm Tumor Section of Resected T1-2N0M0 Lung Cancer Predict Clinical Outcome - PDF(Slides)

Back to course

Pdf Summary

This pilot study aimed to investigate the intratumoral immune profile in patients with T1-2N0M0 non-small cell lung cancer (NSCLC) and its association with recurrence risk and clinical outcomes. The study used the NanoString GeoMx Digital Spatial Profiler (GeoMxDSP) to detect intratumoral immuno-RNA abundance in tumor tissue. The researchers analyzed the RNA expression in pathologically defined "Inflamed/Hot" and "Main/Cold" tumor areas. <br /><br />A total of 38 patients with T1-2N0M0 NSCLC were included in the study. The patients were followed up for subsequent tumors based on medical records. The mean age at primary tumor diagnosis was 66 years, with 45% being female and 21% never-smokers. The study classified the second tumors into recurrence (REC), second primary tumor (2P), equivocal (EQU), or none of the above categories. <br /><br />The researchers identified two immuno-RNA panels that could assist in classifying clinically and pathologically equivocal tumors into REC or 2P. Descriptive analyses of overall and differential RNA expression signals were conducted to assess any differences within and between the morphological regions of interest (Hot, Cold) of the outcome groups. <br /><br />Survival analysis and predictive models of immune response markers were conducted using R software. Cox models were run separately for REC and 2P groups, adjusting for potential confounders. The study also presented a heatmap visualizing correlations between tissue samples and RNA markers.<br /><br />The study does have some limitations, including a small sample size and incomplete analyses. Ongoing and future directions of the research include morphology- and segment-specific analyses, protein marker analyses, and functional immune-response and pathway-based analyses.<br /><br />In conclusion, this pilot study demonstrates the feasibility of analyzing the immune profile of a patient's tumor and its correlation with recurrence or second primary tumor. Further research using a larger sample size and comprehensive analyses is warranted.

Asset Subtitle

Ping Yang

Meta Tag

Speaker Ping Yang

Topic Pathology & Biomarkers: Prognostic Biomarkers

Keywords

pilot study

intratumoral immune profile

T1-2N0M0 non-small cell lung cancer

NSCLC

recurrence risk

clinical outcomes

NanoString GeoMx Digital Spatial Profiler

intratumoral immuno-RNA abundance

Inflamed/Hot tumor areas

Main/Cold tumor areas